Even all 18% are from T315I, it doesn't mean these are overlapping patients. Ponatinib MCyR in T315I is about 70%. To me, it is more likely different patients respond to the two drugs than exactly same patients.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.